UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/789,944	02/26/2004	William R. Patterson	355492-3100	5793
38706 FOLEY & LA	7590 10/26/2007 RDNFR LLP		EXAMINER	
1530 PAGE M	ILL ROAD		ROGERS, JAMES WILLIAM	
PALO ALTO,	CA 94304		ART UNIT	PAPER NUMBER
			1618	
			MAIL DATE	DELIVERY MODE
			10/26/2007	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)				
Office Action Summary	10/789,944	PATTERSON ET AL.				
omee Action Gammary	Examiner	Art Unit				
The MAILING DATE of this communication app	James W. Rogers, Ph.D.	1618				
Period for Reply	ears on the cover sheet with the t	correspondence address				
A SHORTENED STATUTORY PERIOD FOR REPLY WHICHEVER IS LONGER, FROM THE MAILING DA  - Extensions of time may be available under the provisions of 37 CFR 1.13 after SIX (6) MONTHS from the mailing date of this communication.  - If NO period for reply is specified above, the maximum statutory period w  - Failure to reply within the set or extended period for reply will, by statute, Any reply received by the Office later than three months after the mailing earned patent term adjustment. See 37 CFR 1.704(b).	ATE OF THIS COMMUNICATIO 16(a). In no event, however, may a reply be till rill apply and will expire SIX (6) MONTHS from cause the application to become ABANDONE	N. mely filed n the mailing date of this communication. ED (35 U.S.C. § 133).				
Status						
1) Responsive to communication(s) filed on 19 Se	1) Responsive to communication(s) filed on 19 September 2007.					
2a) ☐ This action is FINAL. 2b) ☐ This	This action is FINAL. 2b) This action is non-final.					
	3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is					
closed in accordance with the practice under Ex parte Quayle, 1935 C.D. 11, 453 O.G. 213.						
Disposition of Claims						
4)	1 <u>48-50</u> is/are withdrawn from con ه re rejected.	sideration				
Application Papers						
9) The specification is objected to by the Examiner.						
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.						
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).						
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).  11) The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.						
Priority under 35 U.S.C. § 119	•	•				
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of:  1. Certified copies of the priority documents 2. Certified copies of the priority documents 3. Copies of the certified copies of the prior application from the International Bureau * See the attached detailed Office action for a list of	s have been received. s have been received in Applicat ity documents have been receiv i (PCT Rule 17.2(a)).	tion No red in this National Stage				
Attachment(s)  1) Notice of References Cited (PTO-892)	4) 🔲 Interview Summary	y (PTO-413)				
2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date / 1/207	Paper No(s)/Mail D 5) Notice of Informal I 6) Other:	Date				

#### **DETAILED ACTION**

The amendment to the claims filed 10/12/2007 has been entered. Applicants have canceled claims 8,14 and 37 added new claim 51 and amended claims 7,9-13, 15-20, 36 and 38-50. Any rejection from the previous office action filed 06/29/2007 not addressed in the office action below has been withdrawn.

## Claim Rejections - 35 USC § 102

The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless -

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

Claims 7,9-13,15-16,20,36 and 38-47 are rejected under 35 U.S.C. 102(b) as being anticipated by Unger et al. (US 6,139,819), for the reasons set forth in the office action filed 06/29/2007.

### Response to Arguments

Applicant's arguments filed 09/19/2007 have been fully considered but they are not persuasive.

Applicants assert that Unger does not disclose whether the amount of viscosity modifier is an affective amount to impart shear thinning and pseudo-plastic properties to the composition. Applicants also assert that Unger does not mention sterilizing the composition and its impact on the thixotropic behavior. Applicants further assert that it is

Application/Control Number: 10/789,944

Art Unit: 1618

not inherent that the shelf life of the compositions of Unger will be the same as their claimed invention and point to [0020] of their own specification as evidence.

The relevance of these assertions is unclear. Clearly any amount of viscosity modifier is capable of having some effect to on shear thinning and give some pseudoplastic properties to the composition. Applicants have not met their burden of demonstrating that the amount of rheological modifier used within Unger will not demonstrate at least some of the above properties on the compositions recited. In regards to applicants assertion that Unger does not teach sterilizing the composition, firstly heat or irradiation is considered by the examiner to be a product by process type of limitation on the preamble of the claim, ("where a patentee defines a structurally complete invention in the claim body and uses the preamble only to state a purpose or intended use for the invention, the preamble is not a claim limitation"); Kropa v. Robie, 187 F.2d at 152, 88 USPQ2d at 480-81. With regard to product by process claim(s), the product disclosed by the prior art is identical to the claimed product, even though (it is made by a somewhat different process/the prior art is silent on the method of making). There is no evidence to show that the claimed process imparts any patentable distinction between the claimed product and that of the prior art. It is also inherent that since the compositions of Unger are administrable by injection they would have to be sterilized prior to injection. Regarding the shelf life of the Unger compositions, applicant's claims clearly overlap in scope with the compositions of Unger, since the two compositions are essentially the same it is inherent that such a composition will have the same properties including shelf life. It appears as though applicants are attempting

to claim a new function or property of an old composition. Where the claimed and prior art products are identical or substantially identical in structure or composition, or are produced by identical or substantially identical processes, a prima facie case or either anticipation or obviousness has been established. Thus the claiming of a new use, new function or unknown property which is inherently present in the prior art does not necessarily make the claim patentable. In re Best, 562 F.2d 1252, 1254, 195 USPQ 430, 433 (CCPA 1977).

# Claim Rejections - 35 USC § 103

The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negatived by the manner in which the invention was made.

The factual inquiries set forth in *Graham* v. *John Deere Co.*, 383 U.S. 1, 148 USPQ 459 (1966), that are applied for establishing a background for determining obviousness under 35 U.S.C. 103(a) are summarized as follows:

- 1. Determining the scope and contents of the prior art.
- 2. Ascertaining the differences between the prior art and the claims at issue.
- 3. Resolving the level of ordinary skill in the pertinent art.
- 4. Considering objective evidence present in the application indicating obviousness or nonobviousness.

This application currently names joint inventors. In considering patentability of the claims under 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation

under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of 35 U.S.C. 103(c) and potential 35 U.S.C. 102(e), (f) or (g) prior art under 35 U.S.C. 103(a).

Claims 7,9-13,15-16,20,36,38-47 and 51 are rejected under 35 U.S.C. 103(a) as being unpatentable over Unger et al. (US 6,139,819, cited previously) in view of Greff et al. (US 5,580,568) in view of Porter et al. (US 2003/0039696 A1, cited previously), this new rejection was necessitated by applicants amendments to the claims and new claim 51.

Unger is disclosed in the previous office action and above. Unger is silent on the type of sterilization treatment and Unger is silent on the rheological modifying agents as claimed within new claim 51.

Greff was disclosed in the previous office action. Greff is used primarily for the disclosure within that it was already well known in the art that embolic compositions were heat sterilized. See col 5 lin 40-48. It would have been obvious to one skilled in the art that heat could have been used to sterilize the composition of Unger since the compositions of both the references above are related to the same field of endeavor, embolic compositions. The motivation to sterilize an embolic composition would obviously be to kill or eliminate any transferable agents (bacteria, viruses) so that the agents would not be introduced directly into the bloodstream when the composition is injected to a subject in need.

Porter was disclosed in the previous office action. Porter is used primarily for the disclosure within that rheology modifying agents were already well known in the art at the time of applicant's invention to be useful in embolic compositions. It would have been prime facie obvious at the time of the invention to a person of ordinary skill in the art to modify the embolic composition disclosed in Unger and add the rheological modifying agents disclosed within Greff. It is generally considered to be prime facie obvious to combine compounds each of which is taught by the prior art to be useful for the same purpose in order to form a composition that is to be used for an identical purpose. The motivation for combining them flows from their having been used individually in the prior art, and from them being recognized in the prior art as useful for the same purpose. As shown by the recited teachings, instant claims are no more than the combination of conventional components found within embolic compositions. It therefore follows that the instant claims define prime facie obvious subject matter.

### Conclusion

No claims are allowed at this time.

Applicant's amendment necessitated the new ground(s) of rejection presented in this Office action. Accordingly, THIS ACTION IS MADE FINAL. See MPEP §706.07(a). Applicant is reminded of the extension of time policy as set forth in 37 CFR 1.136(a).

A shortened statutory period for reply to this final action is set to expire THREE MONTHS from the mailing date of this action. In the event a first reply is filed within TWO MONTHS of the mailing date of this final action and the advisory action is not ... mailed until after the end of the THREE-MONTH shortened statutory period, then the

Application/Control Number: 10/789,944 Page 7

Art Unit: 1618

shortened statutory period will expire on the date the advisory action is mailed, and any extension fee pursuant to 37 CFR 1.136(a) will be calculated from the mailing date of the advisory action. In no event, however, will the statutory period for reply expire later than SIX MONTHS from the mailing date of this final action.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to James W. Rogers, Ph.D. whose telephone number is (571) 272-7838. The examiner can normally be reached on 8:30-5:00.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Mike Hartley can be reached on (571) 271-0616. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status

have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

information for unpublished applications is available through Private PAIR only. For

more information about the PAIR system, see http://pair-direct.uspto.gov. Should you

MICHAEL G. HARTLEY
SUPERVISORY PATENT EXAMINER